Investigating blood disorders in ovarian cancer survivors
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
This study is looking at how treatments for ovarian cancer might cause blood disorders later on, and it's for ovarian cancer survivors who want to help researchers find ways to prevent these issues and improve future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11078343 on NIH RePORTER |
What this research studies
This research focuses on understanding how chemotherapy and maintenance therapies for ovarian cancer can lead to long-term blood disorders, specifically therapy-related myeloid neoplasia (TMN). By enrolling 2000 ovarian cancer survivors, the study aims to identify early signs of clonal hematopoiesis, a pre-malignant condition that can precede TMN. The research will explore the natural progression of these blood disorders and seek to develop safer treatment strategies for ovarian cancer patients. Through this approach, the team hopes to provide insights that could lead to interventions that prevent the development of serious blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who have survived ovarian cancer and have undergone chemotherapy or maintenance therapy.
Not a fit: Patients who have not been diagnosed with ovarian cancer or have not received chemotherapy are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for ovarian cancer patients and potentially prevent the development of life-threatening blood disorders.
How similar studies have performed: Previous research has shown that understanding clonal hematopoiesis can provide valuable insights into the progression of blood cancers, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Swisher, Elizabeth Mary — University of Washington
- Study coordinator: Swisher, Elizabeth Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.